CANbridge Pharmaceuticals Inc. (HKG:1228)
2.005
+0.095 (4.97%)
Sep 18, 2026, 4:08 PM HKT
CANbridge Pharmaceuticals Revenue
CANbridge Pharmaceuticals had revenue of 27.94M CNY in the half year ending June 30, 2026, a decrease of -37.63%. This brings the company's revenue in the last twelve months to 55.68M, down -11.00% year-over-year. In the year 2025, CANbridge Pharmaceuticals had annual revenue of 49.98M, down -41.27%.
Revenue (ttm)
55.68M CNY
Revenue Growth
-11.00%
P/S Ratio
18.64
Revenue / Employee
1.43M CNY
Employees
39
Market Cap
1.20B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 49.98M | -35.12M | -41.27% |
| Dec 31, 2024 | 85.10M | -17.77M | -17.27% |
| Dec 31, 2023 | 102.87M | 23.90M | 30.26% |
| Dec 31, 2022 | 78.97M | 47.81M | 153.43% |
| Dec 31, 2021 | 31.16M | 19.13M | 158.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.50B |
| Shandong Boan Biotechnology | 720.87M |
| JW (Cayman) Therapeutics Co. | 333.25M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 170.32M |
| Kintor Pharmaceutical | 90.90M |
| Beijing Biostar Pharmaceuticals | 63.74M |
| Zhaoke Ophthalmology | 40.41M |
| SinoMab BioScience | 6.28M |
CANbridge Pharmaceuticals News
- 20 days ago - CANbridge Posts H1 Loss Despite Higher Revenue; Stock Down - Nasdaq
- 23 days ago - CANbridge Pharmaceuticals Earnings release: H1 2026 - Filings
- 5 months ago - CANbridge Pharmaceuticals Earnings release: H2 2025 - Filings
- 5 months ago - CANbridge Pharmaceuticals Annual report: H2 2025 - Filings
- 1 year ago - China's Push To Expand Access To Costly Therapies And A Partnership Deal Boost Rare Drugs Maker - But Is It Enough? - Benzinga